Athira Pharma Statistics

Total Valuation

Athira Pharma has a market cap or net worth of $27.88 million. The enterprise value is -$65.76 million.

Market Cap	27.88M
Enterprise Value	-65.76M

Important Dates

The next estimated earnings date is Friday, November 15, 2024, after market close.

Earnings Date	Nov 15, 2024
Ex-Dividend Date	n/a

Share Statistics

Athira Pharma has 38.44 million shares outstanding. The number of shares has increased by 0.83% in one year.

Current Share Class	n/a
Shares Outstanding	38.44M
Shares Change (YoY)	+0.83%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	7.61%
Owned by Institutions (%)	32.82%
Float	26.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.30
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.97, with a Debt / Equity ratio of 0.02.

Current Ratio	3.97
Quick Ratio	3.47
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -84.57% and return on invested capital (ROIC) is -55.90%.

Return on Equity (ROE)	-84.57%
Return on Assets (ROA)	-47.53%
Return on Capital (ROIC)	-55.90%
Revenue Per Employee	n/a
Profits Per Employee	-$1.69M
Employee Count	67
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.46% in the last 52 weeks. The beta is 2.83, so Athira Pharma's price volatility has been higher than the market average.

Beta (5Y)	2.83
52-Week Price Change	-55.46%
50-Day Moving Average	0.74
200-Day Moving Average	2.31
Relative Strength Index (RSI)	61.46
Average Volume (20 Days)	13,557,614

Short Selling Information

The latest short interest is 1.56 million, so 4.05% of the outstanding shares have been sold short.

Short Interest	1.56M
Short Previous Month	1.57M
Short % of Shares Out	4.05%
Short % of Float	5.78%
Short Ratio (days to cover)	2.74

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-121.40M
Pretax Income	-113.45M
Net Income	-113.45M
EBITDA	-120.43M
EBIT	-121.40M
Earnings Per Share (EPS)	-$2.97

Full Income Statement

Balance Sheet

The company has $91.77 million in cash and $1.41 million in debt, giving a net cash position of $90.36 million or $2.35 per share.

Cash & Cash Equivalents	91.77M
Total Debt	1.41M
Net Cash	90.36M
Net Cash Per Share	$2.35
Equity (Book Value)	83.34M
Book Value Per Share	2.17
Working Capital	79.80M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$98.41 million and capital expenditures -$63,000, giving a free cash flow of -$98.47 million.

Operating Cash Flow	-98.41M
Capital Expenditures	-63,000
Free Cash Flow	-98.47M
FCF Per Share	-$2.56

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Athira Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.83%
Shareholder Yield	-0.83%
Earnings Yield	-461.23%
FCF Yield	-400.34%

Analyst Forecast

The average price target for Athira Pharma is $11.25, which is 1,451.30% higher than the current price. The consensus rating is "Buy".

Price Target	$11.25
Price Target Difference	1,451.30%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1